• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用具有链接死亡率信息的真实世界数据分析生存情况时,不同删失方法的影响:一项模拟研究。

The impact of different censoring methods for analyzing survival using real-world data with linked mortality information: a simulation study.

机构信息

Genesis Research Group, 111 River St, Ste 1120, Hoboken, NJ, 07030, USA.

出版信息

BMC Med Res Methodol. 2024 Sep 13;24(1):203. doi: 10.1186/s12874-024-02313-3.

DOI:10.1186/s12874-024-02313-3
PMID:39272007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11395225/
Abstract

BACKGROUND

Evaluating outcome reliability is critical in real-world evidence studies. Overall survival is a common outcome in these studies; however, its capture in real-world data (RWD) sources is often incomplete and supplemented with linked mortality information from external sources. Conflicting recommendations exist for censoring overall survival in real-world evidence studies. This simulation study aimed to understand the impact of different censoring methods on estimating median survival and log hazard ratios when external mortality information is partially captured.

METHODS

We used Monte Carlo simulation to emulate a non-randomized comparative effectiveness study of two treatments with RWD from electronic health records and linked external mortality data. We simulated the time to death, the time to last database activity, and the time to data cutoff. Death events after the last database activity were attributed to linked external mortality data and randomly set to missing to reflect the sensitivity of contemporary real-world data sources. Two censoring schemes were evaluated: (1) censoring at the last activity date and (2) censoring at the end of data availability (data cutoff) without an observed death. We assessed the performance of each method in estimating median survival and log hazard ratios using bias, coverage, variance, and rejection rate under varying amounts of incomplete mortality information and varying treatment effects, length of follow-up, and sample size.

RESULTS

When mortality information was fully captured, median survival estimates were unbiased when censoring at data cutoff and underestimated when censoring at the last activity. When linked mortality information was missing, censoring at the last activity date underestimated the median survival, while censoring at the data cutoff overestimated it. As missing linked mortality information increased, bias decreased when censoring at the last activity date and increased when censoring at data cutoff.

CONCLUSIONS

Researchers should consider the completeness of linked external mortality information when choosing how to censor the analysis of overall survival using RWD. Substantial bias in median survival estimates can occur if an inappropriate censoring scheme is selected. We advocate for RWD providers to perform validation studies of their mortality data and publish their findings to inform methodological decisions better.

摘要

背景

在真实世界证据研究中,评估结局可靠性至关重要。总生存是这些研究中的常见结局;然而,其在真实世界数据(RWD)来源中的捕获往往不完整,并通过外部来源的链接死亡率信息进行补充。对于真实世界证据研究中总生存的删失,存在相互矛盾的建议。本模拟研究旨在了解当部分捕获外部死亡率信息时,不同删失方法对估计中位生存时间和对数风险比的影响。

方法

我们使用蒙特卡罗模拟来模拟来自电子健康记录和链接外部死亡率数据的 RWD 的两项治疗的非随机对照有效性研究。我们模拟了死亡时间、最后数据库活动时间和数据截止时间。最后数据库活动后的死亡事件归因于链接的外部死亡率数据,并随机设置为缺失,以反映当代真实世界数据源的敏感性。评估了两种删失方案:(1)在最后一次活动日期进行删失;(2)在数据可用性结束时(数据截止)进行删失,而不观察到死亡。我们根据不完全死亡率信息的数量和不同的治疗效果、随访时间和样本量,评估了每种方法在估计中位生存时间和对数风险比方面的表现,包括偏差、覆盖度、方差和拒绝率。

结果

当完全捕获死亡率信息时,在数据截止时进行删失时中位生存估计值无偏,而在最后一次活动时进行删失时低估。当链接的死亡率信息缺失时,在最后一次活动日期进行删失会低估中位生存时间,而在数据截止时进行删失会高估。随着缺失链接的死亡率信息的增加,在最后一次活动日期进行删失时的偏差减小,而在数据截止时进行删失时的偏差增加。

结论

研究人员在选择如何使用 RWD 分析总生存时,应考虑链接外部死亡率信息的完整性。如果选择了不合适的删失方案,中位生存估计值可能会出现很大的偏差。我们主张 RWD 提供者对其死亡率数据进行验证研究,并发布研究结果以更好地为方法学决策提供信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a2/11395225/635ec68ec8ce/12874_2024_2313_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a2/11395225/f9615f5d1653/12874_2024_2313_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a2/11395225/864b9febb2f9/12874_2024_2313_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a2/11395225/635ec68ec8ce/12874_2024_2313_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a2/11395225/f9615f5d1653/12874_2024_2313_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a2/11395225/864b9febb2f9/12874_2024_2313_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55a2/11395225/635ec68ec8ce/12874_2024_2313_Fig3_HTML.jpg

相似文献

1
The impact of different censoring methods for analyzing survival using real-world data with linked mortality information: a simulation study.利用具有链接死亡率信息的真实世界数据分析生存情况时,不同删失方法的影响:一项模拟研究。
BMC Med Res Methodol. 2024 Sep 13;24(1):203. doi: 10.1186/s12874-024-02313-3.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Censoring for Loss to Follow-up in Time-to-event Analyses of Composite Outcomes or in the Presence of Competing Risks.对复合结局或存在竞争风险的时间事件分析中的失随访进行删失。
Epidemiology. 2019 Nov;30(6):817-824. doi: 10.1097/EDE.0000000000001073.
4
Survival analysis under imperfect record linkage using historic census data.基于历史人口普查数据的不完全记录链接下的生存分析。
BMC Med Res Methodol. 2024 Mar 13;24(1):67. doi: 10.1186/s12874-024-02194-6.
5
Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.两阶段估计调整随机试验中的治疗转换:一项使用逆概率加权而不是重新分类来调整的模拟研究。
BMC Med Res Methodol. 2019 Mar 29;19(1):69. doi: 10.1186/s12874-019-0709-9.
6
An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database.在电子健康记录数据库中评估缺失死亡对晚期非小细胞肺癌患者总体生存分析的影响。
Pharmacoepidemiol Drug Saf. 2019 May;28(5):572-581. doi: 10.1002/pds.4758. Epub 2019 Mar 14.
7
Handling missing disease information due to death in diseases that need two visits to diagnose.处理因需要两次就诊才能确诊的疾病而导致的死亡引起的疾病信息缺失。
Stat Med. 2024 Apr 30;43(9):1708-1725. doi: 10.1002/sim.10038. Epub 2024 Feb 21.
8
Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?在存在治疗转换的随机试验中对长期生存的因果推断:在估计反事实生存时间时是否应该重新删失?
Stat Methods Med Res. 2019 Aug;28(8):2475-2493. doi: 10.1177/0962280218780856. Epub 2018 Jun 25.
9
Impact of censoring on learning Bayesian networks in survival modelling.生存模型中删失数据对贝叶斯网络学习的影响。
Artif Intell Med. 2009 Nov;47(3):199-217. doi: 10.1016/j.artmed.2009.08.001. Epub 2009 Oct 14.
10
How serious is bias in effect estimation in randomised trials with survival data given risk heterogeneity and informative censoring?在存在风险异质性和信息删失的情况下,生存数据的随机试验中效应估计的偏倚有多严重?
Stat Med. 2017 Sep 20;36(21):3315-3333. doi: 10.1002/sim.7343. Epub 2017 Jun 15.

引用本文的文献

1
Behavior of test specificity under an imperfect gold standard: findings from a simulation study and analysis of real-world oncology data.在不完善金标准下测试特异性的表现:模拟研究结果及真实世界肿瘤学数据分析
BMC Med Res Methodol. 2025 May 30;25(1):151. doi: 10.1186/s12874-025-02603-4.

本文引用的文献

1
Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions.有效利用 RWD 进行外部控制:监管和 HTA 决策的系统文献回顾。
Clin Pharmacol Ther. 2023 Aug;114(2):325-355. doi: 10.1002/cpt.2914. Epub 2023 Jun 9.
2
Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021.肿瘤学临床试验中外对照臂的当前观点:对2016 - 2021年欧洲药品管理局批准情况的分析
J Cancer Policy. 2023 Mar;35:100403. doi: 10.1016/j.jcpo.2023.100403. Epub 2023 Jan 14.
3
Real-World Evidence - Where Are We Now?
真实世界证据——我们目前处于什么阶段?
N Engl J Med. 2022 May 5;386(18):1680-1682. doi: 10.1056/NEJMp2200089. Epub 2022 Apr 30.
4
Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products.真实世界数据:评估电子健康记录和医疗理赔数据以支持药品和生物制品的监管决策。
Pharmacoepidemiol Drug Saf. 2022 Jul;31(7):717-720. doi: 10.1002/pds.5444. Epub 2022 May 3.
5
The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications.真实世界证据在 FDA 批准新药和生物制品许可申请中的作用。
Clin Pharmacol Ther. 2022 Jan;111(1):135-144. doi: 10.1002/cpt.2474. Epub 2021 Nov 22.
6
The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework.结构化的适用于目的的数据识别过程:数据可行性评估框架。
Clin Pharmacol Ther. 2022 Jan;111(1):122-134. doi: 10.1002/cpt.2466. Epub 2021 Dec 1.
7
Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model.在监管决策过程中整合真实世界证据:使用逻辑模型对美国、欧盟和中国的经验进行系统分析。
Front Med (Lausanne). 2021 May 31;8:669509. doi: 10.3389/fmed.2021.669509. eCollection 2021.
8
The Use of External Controls in FDA Regulatory Decision Making.在 FDA 监管决策中使用外部对照。
Ther Innov Regul Sci. 2021 Sep;55(5):1019-1035. doi: 10.1007/s43441-021-00302-y. Epub 2021 May 20.
9
Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States.美国癌症患者复合真实世界死亡率终点的验证分析。
Health Serv Res. 2021 Dec;56(6):1281-1287. doi: 10.1111/1475-6773.13669. Epub 2021 May 17.
10
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.2000 年至 2016 年间支持美国食品和药物管理局批准新型癌症疗法的临床试验证据。
JAMA Netw Open. 2020 Nov 2;3(11):e2024406. doi: 10.1001/jamanetworkopen.2020.24406.